Covaxin receives approval for emergency use for 12-18 years age group

Prameyanews English

Published By : Prameya News Bureau | December 25, 2021 IST

New Delhi, Dec 25: The Drugs Controller General of India (DCGI) has granted emergency use authorisation to Covaxin for 12-18 years age group with certain conditions. Earlier the Bharat Biotech has submitted data from clinical trials in the 2-18 years age group for Covaxin (BBV152) to Central Drugs Standard Control Organisation (CDSCO). The data has been thoroughly reviewed by the CDSCO and Subject Experts Committee (SEC) who have provided their positive recommendations. “ Covaxin is formulated uniquely such that the same dosage can be administered to adults and children.  It has established a proven record for safety and efficacy in adults for the original variant and subsequent variants. We have documented excellent safety and immunogenicity data readouts in children. We look forward for Covaxin to provide similar levels of protection for adults and children alike,” said an official of Bharat Biotech.

News7 Is Now On WhatsApp Join And Get Latest News Updates Delivered To You Via WhatsApp

You Might Also Like

More From Related News

Copyright © 2024 - Summa Real Media Private Limited. All Rights Reserved.